

PET Imaging for Clinical and Preclinical Imaging

W

W

Robert S. Miyaoka, PhD Department of Radiology University of Washington



Disclosures

- 1) Research contract with Philips Healthcare
- 2) NIH Academic industrial partnership: Philips Healthcare (PI)
- 3) NIH Academic industrial partnership: GE Healthcare (co-inv)
- 4) NIH STTR: PETX LLC (sub contract: PI)

Acknowlegements: NIH grants R01CA136569, R01CA163498, R41CA180191 and R21EB013716

Advanced PET Instrumentation 🐨 Developments

- 1) Digital photon counting PET detectors
- 2) Time-of-flight PET/MRI scanners
- 3) Time-of-flight with depth of interaction PET detectors
- 4) Advance motion correction methods
- 5) Advance image reconstructions
- 6) Organ specific imaging systems (e.g., breast)
- 7) Operator friendly, desktop pre-clinical PET imaging systems

Advanced PET Instrumentation The Developments

- 1) Digital photon counting PET detectors
- 2) Time-of-flight PET/MRI scanners
- 3) Time-of-flight with depth of interaction PET detectors
- 4) Advance motion correction methods
- 5) Advance image reconstructions
- 6) Organ specific imaging systems (e.g., breast)
- 7) Operator friendly, desktop pre-clinical PET imaging systems





dSiPM - DPC uses intrinsic binary nature of SPADs (SPAD – Single Photon Avalanche Diode)



"Therefore, while the APD is a linear amplifier for the input optical signal with limited gain, the SPAD is a trigger device so the gain concept is meaningless." (source: Wikipedia)

PHILIPS

Digital Photon Counter is an integrated, scalable solution



DPC: dark count management by digitization



 Silicon based light sensors have background noise (dark counts), varying with temperature.

· In digital SiPMs every cell can be addressed individually.

Cells with high dark counts can be switched off.

 A few cells switched off (1-5%) reduces dark count levels by orders of magnitude.

PHILIPS

Performance comparison: Analog versus Digital PET

	Analog*	Digital**
Coincidence timging (psec)	591	307
Image resolution (FWHM, mm)	4.7	4.0
Energy resolution (@511 keV)	13.0%	11.2%

* Philips Gemini Time-of-flight PET; ** Philips Vereos digital PET/CT

PHILIPS

Motivation PET: clinically useful sens. gain ToF-PET rel. sensitivity gain as f(CRT) 6 - D = 20 cm 5 rel. sensitivity gain – D = 30 cm

500

Data calculated after: J.S. Karp et.al. JNM, 49/3, 462-470, 2008

250

D = 40 cm

1000

1 0





Analog (TOF)

Images courtesy of University Hospital Cleveland



Variance reduction = Sensitivity Gain = D/ 🛆 x

100 **PHILIPS**

Digital (TOF) PHILIPS



Images courtesy of University Hospital Cleveland

PHILIPS



Images courtesy of University Hospital Cleveland

Digital (TOF) PHILIPS

Why add depth of interaction?

- 1) Depth of interaction reduces positioning paralax errors
- 2) PET/MRI smaller detector ring diameters
- 3) Smaller detector ring diameters to reduce cost of systems
- 4) Future generation, long axial field of view systems

Parallax Error - Depth-of-interaction (DOI)



Smaller detector ring diameter and longer axial FOV accentuate spatial resolution blurring from parallax errors.





Explorer

 Combining time-of-flight (TOF) and depth-of-interaction (DOI) especially important for long axial field-of-view PET scanners.

Long LORs have axial DOI blurring

High attenuation introduces need for TOF





Explorer

Combining time-of-flight (TOF) and depth-of-interaction (DOI) especially important for long axial field-of-view PET scanners.

- Long LORs have axial DOI blurring
- · High attenuation introduces need for TOF

Long axial FOV PET





Uncoated

10 120

Phosphor coated 3x3x20 mm3 LYSO

Phosphor (YAG:Ce) coated

crystals

Тор

Third one side

Third all sides



















PET Imaging of Breast Cancer



Avril, et al. JCO 2000

"Partial volume effects and varying metabolic activity (dependent on tumor type) seem to represent the most significant limitations for the routine diagnostic application of PET. The number of invasive procedures is

Whole-body PET

 spatial resolution is not sufficient for imaging early-stage breast cancer
 potential for detection of recurrence

puter monitoring in the set cancer patients. Although studies have proven its accuracy in detection

potential for selection/monitoring therapy

restricted to relatively advanced disease

constants return norm safe street or track? Denote the minimum streets of the minimum streets and the streets of the streets o

macdon@uw.edu



The Problem: Variable Responses



- Despite several biomarker targets (e.g., tumor phenotype, receptor status) used to characterize the cancer and help determine treatment, cancer therapy efficacy is highly variable
- As of 2007, there were 30 approved breast cancer therapies, the most of any cancer
- There are limited means for early evaluation of the success of therapy
 typically takes months after surgery to measure response with imaging Consequences in cases of ineffective therapies:
 - * delays effective treatment; earlier treatment is known to improve outcomes
 - $\boldsymbol{*}$ patients suffer side-effects associated with the ineffective therapy without benefits
 - * treatments are very costly

Over 200,000 women in the United States are diagnosed each year with breast cancer (~40,000 mortalities/yr)

macdon@uw.edu



PET/X Proposed Clinical Paradigm W

After diagnosis, use PET tracer uptake as therapy assessment biomarker



Duration of 'window of opportunity' will be case/patient dependent (e.g. see Gebhart et al., JNM 2013)

Related ongoing research at UW

- "Farly Assessment of Response to Aronatase Inhibitor (AI) Therapy", Linden, et al., ASCO 2009
 "Fluronestradiol (FES) Position Emission Tomography (PET) Reveals Differences In
 Pharmacodynamics Of Aromatase Inhibitors, Tamordin, And Fulvestrant In Patients With Metastatic
 Breast Cancer", Linden et al., Clin Cancer Res 17(14):4799-4805, 2011
 "Jounnitative Flurosestradio Positro Emission Tomography Imaging Predicts Response to
 Endocrine Treatment in Breast Cancer", Linden et al., JCO 24(18):2733-2799, 2006

macdon@uw.edu



macdon@uw.edu









Summary: PET/X



Quantitative Breast PET as a Cancer Biomarker

- Many targeted breast cancer therapies exist
 efficacy is variable
 cost is high
- Primary tumor is resected; recurrence or lack thereof determines therapy efficacy
 failure of first-line therapy means
 effective treatments is delayed, degrading outcomes
 suffer side-effects with no benefit
 high cost to healthcare system and patients
- Quantitative PET is showing promise for predicting therapy response earlier than existing methods in several cancers
 WB+PET spatial resolution deemed insufficient for tumors <~ 2-3 cm
 majority of new BC cases present with tumors <~ 2 cm
- PET/X detector design photon sensitivity vs. spatial resolution trade-off will favor quantitative accuracy and precision
- Most dedicated breast PET systems have focused on detection/diagnosis task
 this is changing as developers now implement quantitative corrections
- Not discussed: integration with mammography and x-ray tomosynthesis
 x-ray image may play important role in PET attenuation correction

macdon@uw.edu

Clinical to Pre-clinical Imaging Systems



SIEMENS

Siemens Inveon PET



20x20 LSO Array
 1.59x1.59x10mm pixel
 Short, Tapered Light Guide
 Hamamatsu C-12 PS-PMT
 Highest packing fraction detector
ring
 25,600 Detector elements





SIEMENS

Siemens Inveon PET

The highest resolution PET system: <1.4mm The highest sensitivity PET system: >10.5% The highest countrate PET system: >2.0Mcps peak NEC The largest FOV: 12.7cm axial x 10cm dia. Best timing resolution: 1.3 nsec (in the system) Best energy resolution: 15% ER (in the system) The only source based attenuation correction in preclinical imaging



mage Courtesy of Dr. J Wiech



SIEMENS



Glypican-3–Targeted ⁸⁹Zr PET Imaging of W Hepatocellular Carcinoma



Sham, Kievit, Grierson, Miyaoka, Yeh, Zhang, Yeung, Minoshima, Park. J Nucl Med, 55:799-804, 2014.













sofieBIOSCIENCES G4 PET/X-ray





G8 PET/CT sofiebiosciences

IMAGING PAIN POINT

High cost and complexity of current PET scanners limit use, access, throughput and require significant support resources

-

New users see PET as too complicated, too expensive, lacks diversity and requires one deal with radiation

- Economic challenges effect everyone
- \$700k \$1M PET scanners represents only a fraction of cost, including service contracts of \$70 \$100k/yr
- Further automation of imaging process to allow experts to focus on more important things
- Provide routine, more affordable access to non-FDG probes
- · Technology to remove fears of radioactivity



SPACE IS PRECIOUS



BREAKING AWAY FROM CONVENTIONAL RING BASED GEOMETRY



Surround the animal with panel detectors





AUTOMATION & LIVE LINK TO THE ANIMAL

- Automatic hook-up for anesthesia and heating
 No more cables
 System takes care of the animal for you











iù iì iù Lung Metastasis 187-705 uptake invesn (%10)







MR Soultions



Future Systems/Applications

- PET combined with fluorescence imaging
- Dual radioisotope PET imaging
- PET for proton and hadron therapy
- PET for neutron therapy
- PET combined with micro-irradiators
- Dedicated organ specific imaging systems
 - brain
 - breast
 - prostate

Acknowledgements

- Ling Shao, Philips Healthcare
- Simon Cherry, UC Davis
- Lawrence MacDonald, UW Radiology
- Arion Chatziioannou, UCLA
- Nam Vu, Sofie Bioscience
- Jonathan Sham, UW Dept of Surgery
- James Park, UW Dept of Surgery